Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announced the formation of a Clinical Advisory Board to support the advancement of its PSX-001 development program in generalized anxiety disorder. The newly established board provides independent clinical and scientific guidance as the company progresses PSX-001 into its next phase of clinical and regulatory development.
The Clinical Advisory Board gathers leading experts in psychiatry, neurobiology, and psychopharmacology to strengthen the scientific rigor and patient-focused approach underlying the company’s development strategy. The board will advise Incannex on clinical trial design, endpoint selection, regulatory engagement, and broader strategic approach for PSX-001. The inaugural PSX-001 Clinical Advisory Board includes C. Neill Epperson, M.D., Robert Freedman Endowed Professor and Chair of the Department of Psychiatry at the University of Colorado School of Medicine, an internationally recognized leader in psychiatry and women’s brain health with more than 30 years of NIH-funded research and over 220 peer-reviewed publications. Charles B. Nemeroff, M.D., Ph.D., Matthew P. Nemeroff Professor and Chair of the Department of Psychiatry and Behavioral Sciences at The University of Texas at Austin Dell Medical School, a globally recognized authority with more than 1,300 scientific articles and reviews. Alan F. Schatzberg, M.D., Kenneth T. Norris, Jr. Professor of Psychiatry Emeritus at Stanford University School of Medicine and Director of the Stanford Mood Disorders Center, a pioneer with more than 700 publications and former President of the American Psychiatric Association and American College of Neuropsychopharmacology.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110636143/Incannex-Healthcare-Announces-Formation-Of-Clinical-Advisory-Board-For-PSX-001-Program